Fujifilm invests $188 million in a new cell culture media production facility

• Fujifilm's fifth media production site will be operated by Fujifilm Irving Technologies

• Tripled the company's current liquid cell culture media production capacity

• More than 100 new jobs, including bioprocessing engineer, manufacturing, production and logistics roles

Fujifilm Corporation (Representative Director and CEO Goto Seiichi) announced a $188 million investment to build a cell culture media manufacturing facility
in Research Triangle Park (RTP) in North Carolina, USA.
The new facility will be operated by Fujifilm Irving Technology, a subsidiary of Fujifilm Corporation, a high-tech company
that develops and delivers advanced cell culture solutions for life science research, bioproduction, cell and gene therapy and medical applications.
The new facility is designed to enable Fujifilm Irving Technologies to help meet the growing demand
for high-quality cell culture media solutions.

The state-of-the-art production facility will exceed 250,000 square feet and is located on 64 acres
at RTP.
The site will support cGMP production of animal-free dry powders and liquid media, adding 800,000 kg/year of dry powder, 3,300,000 L/year of liquid, and 40,000 L/day of additional production
capacity for water for injection (WFI) for Fujifilm Irwin Technologies.

Fujifilm Irving Technologies has experienced rapid growth over the past decade and is expected to grow at a CAGR of 10-12% through 2031*
.
In order to meet the needs of its customers, the company made a strategic decision to expand its production capacity
by building plants in biotechnology centers around the world.
The strategy provides a stable supply chain and fast, reliable product delivery by developing an extensive regional supply network, which is essential
to support cell and gene therapy.

The regional supply network shares Fujifilm Irvine Technologies' unified quality system and raw material program, enabling the company to quickly adapt to natural disasters or unforeseen problems, continue operations and deliver products
to customers worldwide.
The Research Triangle Park area of North Carolina is popular with many life sciences companies, and Fujifilm chose it as an ideal location not only to enhance the stability of the supply chain, but also to provide customers in the region with more efficient transportation and faster delivery
.
The Fujifilm Group also has cell culture media production plants
in California, the Netherlands, and Saitama and Aichi prefectures in Japan.

Goto Seiichi, Representative Director and CEO of Fujifilm Corporation, said, "Fujifilm's significant investment in life sciences represents our commitment to being a loyal partner
to our customers in the biopharmaceutical industry.
As our global cell culture media manufacturing sites become more capable, we will continue to contribute to the creation of robust manufacturing processes and innovative therapies for our customers to make the world a healthier
place.
" "

"Our customers need fast and reliable delivery of cell culture media to support their commercial production, and the production of cell culture media at the new facility in North Carolina will help stabilize the supply of raw materials for biologics, cell and gene therapies, and other critical medicines
critical to human health," said Toyo Yamaguchi, Chairman and CEO of Fujifilm Irving Technologies.
The additional production capacity will enable us to help meet the anticipated demand
for cell culture media from customers around the world.
"

Sig Hutchinson, Chairman of the Wake County Council, said: "We are proud that Fujifilm Irving Technologies has 'settled' in Research Triangle Park (RTP), which has brought many new jobs
.
We at RTP provide life sciences companies with top-notch talent, easy access to transportation and high-quality living facilities
.
"

Scott Levitan, President and CEO of the Research Triangle Foundation, said, "We are honored to see companies that have already had a successful experience at Research Triangle Park further recognize the strengths here and continue to invest and innovate
here.
We are also pleased to work
with Fujifilm Corporation and its consultants, our regional partners in Wake County Economic Development, the North Carolina Economic Development Partnership and the North Carolina Department of Commerce on this project.
" "

Land development and construction are scheduled to begin in spring 2023, and the plant will begin operations
in 2025.

　　*Bioplan, "Culture Media Market and Trends", 2020

News Background:

About Fujifilm Irving Technology

Fujifilm Irving Technologies is a high-tech company that innovates and manufactures cell culture solutions for the life sciences and medical markets, providing products and services that help our customers advance their healthcare initiatives
.
The company is trusted
by researchers, manufacturers, and clinicians for drug discovery, cell and gene therapy, reproductive medicine and cytogenetics, and the large-scale production of biotherapeutics and vaccines.
For more than 50 years, our mission has been to set stringent quality standards for our products and customized solutions that enable our customers to advance healthcare projects
.
Our facilities comply with ISO and FDA regulations, our manufacturing facilities follow cGMP guidelines in the US, Japan and the Netherlands, and we have a media optimization center
in China.
To achieve sustainable growth, all factories prioritize compliance with the Fujifilm 2030 Sustainable Value Plan
.
FUJIFILM Irvine Scientific, Inc.
is a subsidiary of FUJIFILM Holdings America Corporation and reports
to FUJIFILM Holdings Corporation.

For more information, please visit: www.
irvinesci.
com
.